UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of February 2025
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Issued: 21 February 2025,
London UK
GSK announces Dr Gavin Screaton to join the Board as Non-Executive
Director
Dr Jesse Goodman to retire after 9 years of service
GSK plc (LSE/NYSE: GSK) has today announced that Dr Gavin Screaton
will join the Board of the Company as a Non-Executive Director from
1 May 2025. Dr Screaton's appointment follows a search to
replace the skills and experience of Dr Jesse Goodman who steps
down from the Board after the company's Annual General Meeting in
May 2025, after nine years of service.
Dr Screaton is currently Head of the
world-leading1 Medical
Sciences Division at the University of Oxford, and an expert in the
field of immunology and infectious diseases, two areas of science
critical to GSK.
Dr Screaton is a Fellow of the Academy of Medical Sciences, a
Fellow of the Royal College of Physicians, and a former Senior
Investigator at the National Institute for Health Research in the
United Kingdom. He is also a Non-Executive Director of Oxford
University Hospitals NHS Foundation Trust and a Trustee of the
Jenner Vaccine Foundation. He also co-founded RQ Bio, a biotech
company focused on development of preventative medicines to provide
immunity and protection against viral infectious
diseases.
On appointment, Dr Screaton will become a member of the GSK Board
Science Committee and the Corporate Responsibility
Committee.
Sir Jonathan Symonds, Chair of GSK said, "We
are delighted to welcome Gavin to the Board of GSK. His deep
expertise in immunology and infectious diseases, which are core
areas of scientific research focus for GSK, together with his
considerable experience in public health, will bring valuable
perspective to the Board.
The appointment will also help to replace the skillset and
experience of Jesse Goodman who steps down from the GSK Board after
nine years of service. As a former FDA Chief Scientist, the Board
as a whole and the Science Committee in particular, has benefitted
hugely from Jesse's wealth of expertise in infectious diseases,
regulation and public health. He has made a fantastic contribution
to GSK and we wish Jesse all the very best for the
future."
_________________________
1The University of Oxford is
ranked first in Times Higher Education (THE) World University
Rankings for Medicine, as of January 2025. This is the 14th
consecutive year that Oxford has led the THE subject rankings in
medicine.
Notes:
|
1.
The appointment of Dr Screaton was made by the Board on the
recommendation of the Nominations & Corporate Governance
Committee. The Committee conducted an extensive search and
selection process for this appointment, using an external search
firm, which is a signatory of the Voluntary Code of Conduct for
Executive Search Firms. The external search firm provided a
comprehensive list of candidates who were approached, evaluated and
interviewed against an agreed set of criteria aligned to the
Board's target skills matrix. The Board satisfied itself that Dr
Screaton had the experience and time available to carry out the
role.
|
|
2.
The Board has determined that Dr Screaton is an independent
Non-Executive Director in accordance with the UK Corporate
Governance Code.
|
|
3.
Dr Screaton will receive the standard basic fee for a Non-Executive
Director of £122,258 per annum (including travel allowance).
He will also receive fees of £30,000 per annum as a scientific
and medical expert. Dr Screaton will be required to build towards a
share ownership requirement of GSK shares in accordance with the
Company's shareholder approved Non-Executive remuneration
policy.
|
|
4.
"Scientific and Medical Expert" - The Board designates
Non-Executive Directors whose expertise or backgrounds as renowned
medical scientists, researchers, or physicians mean that they can
bring scientific or industry expertise to the Board's
deliberations.
|
|
5.
Dr Screaton does not have a service contract. He has a letter of
appointment which may be viewed by contacting the Company Secretary
at the Company's registered office.
|
|
6.
There are no further disclosures to be made in respect of Dr
Screaton's appointment under Listing Rule 6.4.8R
|
|
7.
As of 1 May 2025, the Board of GSK will comprise:
|
|
Sir
Jonathan Symonds
|
Non-Executive
Chair
|
|
Emma
Walmsley
|
Chief
Executive Officer
|
|
Julie
Brown
|
Chief
Financial Officer
|
|
Charles
Bancroft
|
Senior
Independent Non-Executive Director
|
|
Elizabeth
McKee Anderson
|
Independent
Non-Executive Director
|
|
Dr Hal
Barron
|
Non-Executive
Director
|
|
Dr Anne
Beal
|
Independent
Non-Executive Director
|
|
Wendy
Becker
|
Independent
Non-Executive Director
|
|
Dr Hal
Dietz
|
Independent
Non-Executive Director
|
|
Dr
Jesse Goodman
|
Independent
Non-Executive Director
|
|
Dr
Jeannie Lee
|
Independent
Non-Executive Director
|
|
Dr
Gavin Screaton
|
Independent
Non-Executive Director
|
|
Dr
Vishal Sikka
|
Independent
Non-Executive Director
|
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at gsk.com.
|
GSK enquiries
|
|
|
|
|
Media:
|
Tim Foley
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
Kathleen Quinn
|
+1 202 603 5003
|
(Washington DC)
|
|
|
|
|
|
|
Investor Relations:
|
Annabel Brownrigg-Gleeson
|
+44 (0) 7901 101944
|
(London)
|
|
|
James Dodwell
|
+44 (0) 20 8047 2406
|
(London)
|
|
|
Mick Readey
|
+44 (0) 7990 339653
|
(London)
|
|
|
Camilla Campbell
|
+44 (0) 7803 050238
|
(London)
|
|
|
Steph Mountifield
|
+44 (0) 7796 707505
|
(London)
|
|
|
Jeff McLaughlin
|
+1 215 751 7002
|
(Philadelphia)
|
|
|
Frannie DeFranco
|
+1 215 751 4855
|
(Philadelphia)
|
Cautionary statement regarding forward-looking
statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described under Item 3.D
"Risk factors" in GSK's Annual Report on Form 20-F for 2023, and
GSK's Q4 Results for 2024.
Registered in England & Wales:
No.
3888792
Registered Office:
79
New Oxford Street
London
WC1A
1DG
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: February
21, 2025
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|